PathNetDRP: a novel biomarker discovery framework using pathway and protein–protein interaction networks for immune checkpoint inhibitor response prediction

Table 1 Descriptions of the Eight ICI Cohort Datasets

No.	Cohort	Cancer	Drug	Responders	Non-	Number of
No.	Name	Type			Responders	Genes
1	Gide	Melanoma	Nivolumab or pembrolizumab,	49	42	54,147
1	Gide	Melanoma	or ipilimumab combination therapy	49	42	54,147
2	Liu	Melanoma	Nivolumab or pembrolizumab	47	72	20,848
3	Kim	Gastric	Pembrolizumab	12	33	18,161
3	Kim	cancer	Pembrolizumab	12	33	18,161
4	IMvigor210	Bladder	Atezolizumab	68	230	18,208
4	IMvigor210	cancer	Atezolizumab	68	230	18,208
5	Auslander	Melanoma	Anti-PD-1 or anit-	3	34	23,762
5	Auslander	Melanoma	CTLA4-treated	3	34	23,762
6	Prat	Melanoma	Nivolumab or pembrolizumab	9	16	784
7	Riaz	Melanoma	Nivolumab	10	39	24,117
8	Huang	Melanoma	Pembrolizumab	8	5	774

ISSN: 1471-2105